Expert Opinion on Investigational Drugs 2002-05-01

Immunomodulation with DiNAC-- a new approach to the treatment of atherosclerosis?

Sheila A Doggrell

文献索引：Expert Opin. Investig. Drugs 11(5) , 717-20, (2002)

全文：HTML全文

摘要

Not all antioxidants reduce atherosclerosis. This may be because atherosclerosis has an autoimmune, inflammatory pathogenesis. As probucol is both an antioxidant and an immunomodulatory drug, it may be the immunomodulatory effect that underlies its ability to reduce atherosclerosis. N,N-Diacetyl-L-cystine is not an antioxidant but is immunomodulatory. In the Watanabe-heritable hyperlipidaemic rabbit model of familial hypercholesterolaemia, N,N-diacetyl-L-cystine treatment does not lower lipid levels but it does reduce atherosclerosis. Immunomodulation may be a new approach to the treatment of atherosclerosis.

相关化合物

  • N,N'-二乙酰基-L-...

相关文献：

Influence of N,N'-diacetyl-L-cystine on D-galactosamine/lipopolysaccharide induced immunological liver failure in mice.

2004-10-01

[Yao Xue Xue Bao 39(10) , 782-6, (2004)]

The new oral immunomodulating drug DiNAC induces brachial artery vasodilatation at rest and during hyperemia in hypercholesterolemic subjects, likely by a nitric oxide-dependent mechanism.

2008-01-01

[Atherosclerosis 196(1) , 275-82, (2008)]

N,N'-Diacetyl-L-cystine-the disulfide dimer of N-acetylcysteine-is a potent modulator of contact sensitivity/delayed type hypersensitivity reactions in rodents.

1999-03-01

[J. Pharmacol. Exp. Ther. 288(3) , 1174-84, (1999)]

Monitoring of the subtraction process in solid-phase representational difference analysis: characterization of a candidate drug.

2001-06-27

[Gene 271(2) , 183-92, (2001)]

[Cysteine in parenteral nutrition: comparative study of N-acetyl-cysteine and N,N-diacetylcystine in the rat model].

1988-04-01

[Infusionstherapie 15(2) , 89-92, (1988)]

更多文献...